Edwards Lifesciences stock maintains $100 target and Buy rating By Investing.com
On Tuesday, Edwards Lifesciences (NYSE:), a prominent player in the medical technology field, retained its Buy rating and a price target of $100.00, as reaffirmed by a leading financial services firm. This endorsement comes amid…